Adenylate cyclase type 5 (ADCY5) (ADCY5)

Adenylate cyclase type 5 (ADCY5) is a membrane-bound enzyme that plays a critical role in intracellular signaling by catalyzing the conversion of adenosine triphosphate (ATP) to the second messenger cyclic adenosine monophosphate (cAMP) [4, 6]. It is predominantly expressed in the striatum of the brain and in cardiac tissue, where it mediates responses to various neurotransmitters and hormones, including dopamine and adenosine [1, 4]. In the striatum, ADCY5 is essential for the regulation of voluntary and involuntary movements through its involvement in the dopaminergic signaling pathway [3, 13]. Mutations in the ADCY5 gene, particularly gain-of-function variants, lead to ADCY5-related movement disorder, a rare condition characterized by chorea, dystonia, and myoclonus [2, 5]. Beyond neurology, ADCY5 is implicated in cardiovascular health, where its inhibition has been shown to provide cardioprotection against heart failure in animal models [4, 16]. It also influences metabolic processes, with certain genetic variants associated with an increased risk of type 2 diabetes and altered insulin secretion [4, 6]. Therapeutic strategies often involve modulating cAMP levels, such as using A2A receptor antagonists like caffeine or theophylline to reduce excessive cAMP production in patients with movement disorders [10, 13].

Other names

Adenylate cyclase 5ATP pyrophosphate-lyase 5Adenylate cyclase type VAC5FDFMDSKOD

Catalyzes the conversion of adenosine triphosphate (ATP) to cyclic adenosine monophosphate (cAMP) and pyrophosphate, acting as a key effector in G protein-coupled receptor signaling.